Biocon launches its first biologic drug for psoriasis
The drug took 10 years in the making and is expected to be launched at 50 per cent lower than the drugs available in the market.
Bengaluru, August 11, 2013: The Indian biotechnology firm Biocon has rolled out its first biologic drug for the treatment of auto immune disease psoriasis. It may be noted here that a biologic is a drug made using cells and not via artificial (chemical) means.
The drug, ALZUMAb, took 10 years in the making and is a recongnition of the innovation done by Biocon’d R&D team. Psoriasis is an auto immune disease affecting 2-3 per cent of the global population and alonst 1-2 per cent within the country. The market size of a biologic of psoriasis is expected to be close to US$ 30 billion and the company is looking for a global partner.
It is interesting to note here that ALZUMAb will also be the world's first novel anti-CD6 antibody to treat psoriasis. Each vial of this drug is expected to be priced around Rs 7950, which is 50 per cent lower than the drugs available in the market.
Biocon spend around 10 per cent of its revenues on R&D.